Private Advisor Group LLC trimmed its position in Edwards Lifesciences Corporation (NYSE:EW) by 7.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,163 shares of the medical research company’s stock after selling 470 shares during the period. Private Advisor Group LLC’s holdings in Edwards Lifesciences Corporation were worth $724,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Edwards Lifesciences Corporation by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 20,341,668 shares of the medical research company’s stock worth $1,913,541,000 after purchasing an additional 505,725 shares in the last quarter. BlackRock Inc. increased its holdings in Edwards Lifesciences Corporation by 2,184.9% during the 1st quarter. BlackRock Inc. now owns 14,003,695 shares of the medical research company’s stock worth $1,317,326,000 after purchasing an additional 13,390,818 shares in the last quarter. State Street Corp increased its holdings in Edwards Lifesciences Corporation by 1.7% during the 1st quarter. State Street Corp now owns 9,388,994 shares of the medical research company’s stock worth $883,219,000 after purchasing an additional 157,844 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Edwards Lifesciences Corporation by 29.8% during the 1st quarter. Alliancebernstein L.P. now owns 6,366,425 shares of the medical research company’s stock worth $598,890,000 after purchasing an additional 1,459,921 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Edwards Lifesciences Corporation by 17.4% during the 1st quarter. Ameriprise Financial Inc. now owns 5,737,459 shares of the medical research company’s stock worth $539,685,000 after purchasing an additional 850,168 shares in the last quarter. 82.36% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Corporation (EW) opened at 114.69 on Wednesday. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75. The company has a 50-day moving average price of $114.37 and a 200 day moving average price of $108.56. The stock has a market cap of $24.22 billion, a P/E ratio of 34.79 and a beta of 0.64.

Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The business had revenue of $842.00 million during the quarter, compared to the consensus estimate of $839.16 million. During the same quarter in the previous year, the firm posted $0.76 EPS. The firm’s revenue was up 10.9% on a year-over-year basis. Equities analysts expect that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

WARNING: This story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/13/edwards-lifesciences-corporation-ew-shares-sold-by-private-advisor-group-llc.html.

A number of analysts have commented on the company. Canaccord Genuity reissued a “buy” rating and set a $155.00 price objective (up from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. BidaskClub lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Zacks Investment Research lowered Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a report on Thursday, June 8th. Jefferies Group LLC reissued a “buy” rating and set a $115.00 price objective on shares of Edwards Lifesciences Corporation in a report on Friday, June 30th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $120.75.

In other news, VP Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $117.15, for a total transaction of $656,040.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $112.45, for a total transaction of $3,699,605.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 163,541 shares of company stock valued at $18,712,719. 2.13% of the stock is currently owned by insiders.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.